ライフサイエンスコーパス: macrolide

1 ry diverse ARGs (multidrug, acriflavine, and macrolide).

2 tives of potency equal to that of the parent macrolide.

3 to positively regulate the synthesis of the macrolide.

4 nd absolute configuration of this oxopolyene macrolide.

5 posite end of selvamicin's shortened polyene macrolide.

6 es for synthesizing custom macrolactones and macrolides.

7 etrahydropyrans, which are found in numerous macrolides.

8 ng prolonged multidrug regimens that include macrolides.

9 persons was 6.9 for moxifloxacin and 1.6 for macrolides.

10 one scaffold of MTM is smaller than in other macrolides.

11 amoxicillin-clavulanate, cephalosporins, and macrolides.

12 parately for penicillins, cephalosporins and macrolides.

13 Macrolides 1 and 2 inhibit mitochondrial function simila

14 6 sulfonamides (SAs), 12 fluoroquinolones, 6 macrolides, 2 ionophores, 2 diaminopyimidines, 1 aminoco

15 thermore, the total synthesis of the related macrolide (2S)-sanctolide A is reported.

16 The 14-membered macrolide 6-deoxyerythronolide B is prepared in 14 steps

17 ls (2), cephalosporins (7), penicillins (8), macrolides (8), benzimidazoles (20), coccidiostats (14),

18 erefore, it appears that the general mode of macrolide action involves selective inhibition of peptid

19 e characteristic of the conventional view of macrolide action, occurs only at a limited number of gen

20 To understand the general mechanism of macrolide action, we used genome-wide ribosome profiling

21 No evidence of emergence of resistance to macrolides against Treponema pallidum subspecies pertenu

22 ding polyketides, glycopeptides, terpenoids, macrolides, alkaloids, carbohydrates, and others.

23 gents that inhibit protein synthesis such as macrolides, along with fluoroquinolones that inhibit DNA

24 biotic treatment (PAT) with a beta-lactam or macrolide alters both host and microbiota development.

25 A formal total synthesis of the cytotoxic macrolide amphidinolide E is reported.

26 ontrolled total synthesis of the 15-membered macrolide, amphidinolide P, is described.

27 e of utility in the rational design of novel macrolide analogs with improved activity against methyla

28 imeras was fully functionalized into a novel macrolide analogue.

29 entifying the subspecies and determining the macrolide and aminoglycoside resistance levels of 50 Myc

30 ohorts consisted of patients prescribed oral macrolide and beta-lactam antibiotics during the study p

31 ed to detect genotypic resistance markers of macrolide and fluoroquinolone antibiotics in 23S ribosom

32 nitalium and associated genotypic markers of macrolide and fluoroquinolone resistance among men sympt

33 the beta-lactam strategy to the beta-lactam-macrolide and fluoroquinolone strategies with respect to

34 ress in this area, including our own work in macrolide and spirocyclic molecule synthesis.

35 third- and fourth-generation cephalosporins, macrolides and ketolides, and glycopeptides.

36 exhibited high-level susceptibility to most macrolides and quinolones, and moderate susceptibility t

37 nverting them to the titled tetrahydropyran, macrolide, and macrodiolide compounds using standard syn

38 , and antibiotics derived from beta-lactams, macrolides, and aminocoumarins.

39 roquinolone, third-generation cephalosporin, macrolides, and carbapenem use, exceeding hospital popul

40 ribing the relative risk of arrhythmias from macrolides, and concludes that this risk has been overes

41 markers to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in 1102 resistant and s

42 The decline in resistance was slowest for macrolides, and in particular for azithromycin.

43 e acquisition of resistance to tetracycline, macrolides, and lincosamides.

44 class: terpenes, alkaloids, prostaglandins, macrolides, and tetracyclines.

45 current large-scale use of fluoroquinolones, macrolides, and third-generation cephalosporins and any

46 istinamycin was highly effective in treating macrolide- and quinolone-resistant strains.

47 Macrolide- and tetracycline-resistant Streptococcus pyog

48 The widely used macrolide antibiotic azithromycin increases risk of card

49 We show that the macrolide antibiotic azithromycin reduced viral prolifer

50 The macrolide antibiotic bafilomycin A1 inhibited CS-induced

51 giogenesis stimulation can be blocked by the macrolide antibiotic borrelidin (BN), which exhibits a b

52 More than 300 new macrolide antibiotic candidates, as well as the clinical

53 Macrolide antibiotic for 3 months was associated with im

54 Ceftriaxone with or without a macrolide antibiotic is a recommended treatment for pati

55 A prolonged course (3 months) of macrolide antibiotic may be considered for patients with

56 Macrolide antibiotic rapamycin, in complex with a cytoso

57 onas vaginalis Sequencing was used to assess macrolide antibiotic resistance among M. genitalium-posi

58 lly transmitted organisms, and high rates of macrolide antibiotic resistance in a diverse sample of s

59 transmitted organisms and the frequency of a macrolide antibiotic resistance phenotype were determine

60 reactionary sites which are complementary to macrolide antibiotic spiramycin (SPI) were synthetized b

61 Treatment depends on macrolide antibiotic therapy and intubation, with assist

62 Here we demonstrate that a single pulsed macrolide antibiotic treatment (PAT) course early in lif

63 proved latrine (0.89; 0.82-0.97), and recent macrolide antibiotic use (0.68; 0.63-0.74).

64 BOTTOM LINE Continuous macrolide antibiotic use for prophylaxis was associated

65 Solithromycin, a novel macrolide antibiotic with both intravenous and oral form

66 , led to the discovery of gladiolin, a novel macrolide antibiotic with potent activity against Mycoba

67 e novel form of proarrhythmia seen with this macrolide antibiotic.

68 provides a platform for the discovery of new macrolide antibiotics and may also serve as the basis fo

69 atal cases were less likely to have received macrolide antibiotics and more likely to have received s

70 transporter has been implicated in efflux of macrolide antibiotics and secretion of enterotoxin STII.

71 resent a practical, fully synthetic route to macrolide antibiotics by the convergent assembly of simp

72 nt data challenged this view by showing that macrolide antibiotics can differentially affect synthesi

73 During antibiotic stewardship, use of 4C and macrolide antibiotics fell by 47% (mean decrease 224 def

74 Macrolide antibiotics have been shown beneficial in cyst

75 ing "plug-in-the-bottle" model suggests that macrolide antibiotics inhibit translation by binding ins

76 The proportion of macrolide antibiotics prescribed increased from 36.8% to

77 have demonstrated that chronic therapy with macrolide antibiotics reduces the morbidity of patients

78 Macrolide antibiotics such as erythromycin may improve c

79 lav, and third-generation cephalosporins, or macrolide antibiotics that exceeded hospital-specific th

80 not, which makes comparisons between these 2 macrolide antibiotics useful in assessing clinically imp

81 uvenimicin, M-4365, and rosamicin classes of macrolide antibiotics via late-stage diversification.

82 Macrolide antibiotics, exemplified by erythromycin, bind

83 induced lethality and identified a series of macrolide antibiotics, including roxithromycin, that pot

84 ch as the prostanoids, indole alkaloids, and macrolide antibiotics, provide ample evidence for the en

85 ling in the presence of clinically important macrolide antibiotics, such as erythromycin, leading to

86 of which were predicted to be susceptible to macrolide antibiotics, suggesting that different strains

87 and actively extrudes substrates, including macrolide antibiotics, virulence factors, peptides and c

88 xposure has ceased.High or multiple doses of macrolide antibiotics, when given early in life, can per

89 Macrolide antibiotics, which have anti-inflammatory and

90 ion experiment over 25 days except for three macrolide antibiotics, which reached saturation at 300 n

91 hrough genetic analysis to be susceptible to macrolide antibiotics.

92 nthesis may modulate site-specific action of macrolide antibiotics.

93 al cells treated with high concentrations of macrolide antibiotics.

94 clav, clindamycin, and fluoroquinolones) and macrolide antibiotics; a hand hygiene campaign; hospital

95 nd their sexual partner(s) is complicated as macrolide antimicrobial resistance is now common in many

96 We used the myxobacterial macrolide archazolid B, a potent inhibitor of the V-ATPa

97 wer levels of evidence indicate that chronic macrolides are also effective in treating patients with

98 Macrolides are among the most widely prescribed antibiot

99 Macrolides are clinically important antibiotics thought

100 Macrolides are known to cause torsade des pointes and ot

101 Our studies suggest that macrolides are useful for treating approximately 20% of

102 However, here we show that macrolides arrest translation of the truncated ErmDL reg

103 The polyhydroxylated 18-membered lichen macrolide (+)-aspicilin was synthesized in 12 steps and

104 Macrolides attain high therapeutic concentrations in inf

105 e strongly associated with resistance to the macrolide azithromycin.

106 of a beta-lactam plus an oral or parenteral macrolide (azithromycin or clarithromycin) served as the

107 ely 6 muM] properties of 16-membered lactone macrolides based on spiramycin's aglycone.

108 dred and eighty patients undergoing standard macrolide-based therapy for M. avium complex lung diseas

109 These results suggest that macrolides be considered first-line combination treatmen

110 While bacteriostatic and bactericidal macrolides bind in the nascent peptide exit tunnel of th

111 To address the buried nature of the macrolide binding site, the number of waters within the

112 ther, TylP is closer in structural design to macrolide-binding TetRs found in pathogens.

113 (+)-chloriolide and the first one ever of a macrolide by a ring-closing Wittig olefination of a stab

114 nce of arrhythmias to the point that chronic macrolides can be used safely in the majority of subject

115 The oral macrolides clarithromycin and azithromycin are commonly

116 icient (14 % overall yield) synthesis of the macrolide (-)-clavosolide A.

117 one cohort, 0.02% (95% CI, 0.01-0.04) of the macrolide cohort, and 0.02% (95% CI, 0.01-0.04) of the b

118 one cohort, 0.02% (95% CI, 0.01-0.03) of the macrolide cohort, and 0.03% (95% CI, 0.02-0.05) of the b

119 noninferior to strategies with a beta-lactam-macrolide combination or fluoroquinolone monotherapy wit

120 am monotherapy (n = 506) vs beta-lactam plus macrolide combination therapy (n = 566), with an absolut

121 beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy among a cohort of children

122 beta-Lactam monotherapy and beta-lactam plus macrolide combination therapy are both common empirical

123 Empirical macrolide combination therapy conferred no benefit over

124 questions about the routine empirical use of macrolide combination therapy in this population.

125 iotic therapy consisting of beta-lactam plus macrolide combination therapy or fluoroquinolone monothe

126 1188 to 24,780) found that beta-lactam plus macrolide combination therapy was associated with relati

127 s) with beta-lactam monotherapy, beta-lactam-macrolide combination therapy, or fluoroquinolone monoth

128 beta-lactam monotherapy vs beta-lactam plus macrolide combination therapy, with an absolute differen

129 on hospital day 7 favoring beta-lactam plus macrolide combination therapy.

130 beta-lactam monotherapy or beta-lactam plus macrolide combination therapy.

131 py and 399 (28.1%) received beta-lactam plus macrolide combination therapy.

132 The sluggish dissociation of bactericidal macrolides correlates with the presence in their structu

133 ur results indicate that a single early-life macrolide course can alter the microbiota and modulate h

134 Here, Ruiz et al. show that even a single macrolide course, given early in life, leads to long-las

135 treatments targeting neutrophils, including macrolides, CXCR2 antagonists, phosphodiesterase 4 inhib

136 motilin receptor agonist, and by synthesized macrolide derivatives lacking antibiotic or motilide act

137 Macrolide-derived selective KCNJ5MUT inhibitors thus hav

138 omycin (1), a third-generation semisynthetic macrolide discovered by combinatorial copper-catalyzed c

139 st to earlier predictions, we found that the macrolide does not preferentially induce ribosome stalli

140 ic resistance genes, activated by binding of macrolide drugs to the ribosome.

141 Macrolide efflux encoded by mef(E)/mel and ribosomal met

142 by the bacterium Streptomyces CBR38; and the macrolides elaiophylin, efomycin A and efomycin G, produ

143 delays lasting several months with previous macrolide exposure.

144 spital MRSA rates and above-threshold use of macrolides, fluoroquinolones, and clindamycin.

145 sus, calling into question the usefulness of macrolides for treating M. abscessus subsp. abscessus in

146 r E. coli 70S ribosomes or 50S subunits with macrolide-functionalized azide 2 and 3-ethynylaniline (3

147 Ipomoeassin F, a macrolide glycoresin containing an embedded disaccharide

148 tingly, the addition of structurally related macrolides had dramatically different effects on stallin

149 bjects experiencing cardiac arrhythmias from macrolides have coexisting risk factors and that the inc

150 At present, the use of macrolides in chronic asthma or acute exacerbations is n

151 ome efficacious against strains resistant to macrolides in current use.

152 evidence suggests improved effectiveness of macrolides in patients with sub-optimally controlled sev

153 ed selvamicin, an unusual antifungal polyene macrolide, in bacterial isolates from two neighboring an

154 stance, particularly to fluoroquinolones and macrolides, in the major foodborne pathogen Campylobacte

155 uidelines recommend combination therapy with macrolides, including azithromycin, as first-line therap

156 the drug binding site can protect cells from macrolide-induced killing, even with inhibitor concentra

157 nd binding properties of chemically distinct macrolide inhibitors of translation, we have identified

158 dynamic studies suggested that TylP binds a macrolide intermediate in the tylosin pathway.

159 Leiodermatolide is an antimitotic macrolide isolated from the marine sponge Leiodermatium

160 astereomers of gliomasolide E, a 14-membered macrolides isolated from the marine sponge Phakellia fus

161 berculosis and M. ulcerans, M. tuberculosis (macrolide-lincosamide-streptogramin resistance protein,

162 Tetracycline, multidrug, macrolide-lincosamide-streptogramin, bacitracin, vancomy

163 erium acnes strains are resistant to topical macrolides, making them less effective.

164 tal synthesis of the highly cytotoxic marine macrolide (-)-mandelalide A (1).

165 Macrolides may therefore be beneficial as adjunct asthma

166 with CABP, showing the potential to restore macrolide monotherapy for this indication.

167 However, because macrolide monotherapy may lead to macrolide resistance,

168 When macrolide monotherapy was excluded, the macrolide mortal

169 When macrolide monotherapy was excluded, the macrolide mortality benefit was maintained (21% [737 of

170 larly selectively inhibited by idremcinal, a macrolide motilin receptor agonist, and by synthesized m

171 disease, Buruli ulcer, produces a cytotoxic macrolide, mycolactone, whose function(s) in the environ

172 nolones were prescribed for 38,046 patients (macrolide n = 48,074, beta-lactam n = 69,079) during the

173 d with the systemic diffusion of a bacterial macrolide named mycolactone.

174 ete the scalable construction of a series of macrolide natural products in as few as 15 linear steps

175 The pooled effect of macrolides on FEV1 (eight trials, 381 subjects) was not

176 Multiple classes of NPs such as macrolides, opioids, steroids, and beta-lactams used to

177 and in oncology and that most belong to the macrolide or cyclic peptide class.

178 undiagnosed NGU, necessitates treatment with macrolides or fluoroquinolones rather than doxycycline,

179 th resistance to beta-lactam antimicrobials, macrolides, or fluoroquinolones.

180 confidence interval [CI], .96-1.00; P = .02; macrolides: OR, 0.98; 95% CI, .96-.99; P = .005; penicil

181 ofloxacin, moxifloxacin, cephalosporins, and macrolides orally were identified.

182 nce to fluoroquinolones, aminoglycosides, or macrolides (P < .001).

183 stereoselective total synthesis of cytotoxic macrolides pestalotioprolides G and H has been developed

184 Cephalosporin and macrolide prescribing decreased but remains common.

185 Overall antibiotic prescription; macrolide prescription; and patient, provider, and setti

186 considered included limiting indications for macrolide prescriptions, introduction of alcohol-based h

187 he evidence from clinical trials and discuss macrolide properties and their relevance to the pathophy

188 treptomyces venezuelae, represent minimalist macrolide protein synthesis inhibitors.

189 gand with affinity comparable to that of the macrolide Rapamycin.

190 ORC2 kinase activity is not inhibited by the macrolide rapamycin.

191 Mycolactone, an immunosuppressive macrolide released by the human pathogen Mycobacterium u

192 d evidence for a relationship between ST and macrolide resistance after mass treatments (P < .0001).

193 ere infected with DLSTs possessing genotypic macrolide resistance and 1 patient was infected with a D

194 thromycin (1.5g over 5 days) on selection of macrolide resistance and microbiological cure in men wit

195 . pneumoniae were associated with changes in macrolide resistance and the molecular basis over time i

196 bronchiectasis, although associated risks of macrolide resistance are poorly defined.

197 cin as first-line treatment, rapid spread of macrolide resistance as well as emergence of quinolone r

198 by acquisition of a cell-surface protein and macrolide resistance determinants via incorporation of a

199 Molecular details associated with macrolide resistance due to the A2058G mutation and meth

200 In the classic mechanism of induction of macrolide resistance genes, antibiotics promote translat

201 Macrolide resistance has been linked to the presence of

202 ause of NGU in this population with rates of macrolide resistance higher than those previously docume

203 ondary aim was to estimate the occurrence of macrolide resistance in a 3-year period.

204 Secondary outcomes included macrolide resistance in commensal oropharyngeal streptoc

205 The erm(41) gene causes inducible macrolide resistance in Mycobacterium abscessus but not

206 The erm(41) gene confers inducible macrolide resistance in Mycobacterium abscessus subsp. a

207 al methylation encoded by erm(B) confer most macrolide resistance in Streptococcus pneumoniae.

208 tion of both point mutations associated with macrolide resistance in T. pallidum.

209 may circulate among low-risk women and that macrolide resistance is substantially lower than in high

210 to induction of expression of the downstream macrolide resistance methyltransferase ErmB.

211 , leading to the induction of the downstream macrolide resistance methyltransferase ErmC.

212 and posttreatment samples were assessed for macrolide resistance mutations (MRMs) by high-resolution

213 Pre- and post-treatment macrolide resistance mutations were detected by sequenci

214 We aimed to determine the effect of macrolide resistance on the presentation and outcomes of

215 conflicting reports describing the effect of macrolide resistance on the presentation and outcomes of

216 A macrolide resistance rate of 88% was noted in azithromyc

217 sequence for known polymorphisms conferring macrolide resistance revealed that all 141 tested to pos

218 Macrolide resistance screening was introduced December 2

219 Macrolide resistance was detected in 38% (385/1008) of t

220 In this nationwide survey, macrolide resistance was found in almost 40% of the spec

221 Overall, macrolide resistance was identified in approximately 10%

222 romycin similarly increased, and circulating macrolide resistance was present in high levels in sever

223 Genotypic macrolide resistance was spread within these 2 clusters.

224 Genetic determinants of macrolide resistance were evaluated using established te

225 E-emm12, encoding genes for tetracycline and macrolide resistance, and prophage PhiHKU.vir, encoding

226 r, because macrolide monotherapy may lead to macrolide resistance, routine screening for NTM should b

227 association with high levels of pretreatment macrolide resistance.

228 importantly did not reduce the selection of macrolide resistance.

229 onary exacerbations and an increased rate of macrolide resistance.

230 ates with MICs of >/=8 mug/ml are considered macrolide resistant by current CLSI guidelines.

231 for S. pneumoniae pneumonia, 139 (22%) were macrolide resistant.

232 cal conjugate vaccine (PCV7) in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IP

233 Following PCV13 introduction, dual macrolide-resistant IPD decreased 74.1% (incidence 0.32/

234 9977T was designated sequevar (type) 1; most macrolide-resistant isolates were of this type.

235 We report a cluster of macrolide-resistant M. pneumoniae cases among a mother a

236 At 0.1 microg/ml erythromycin, macrolide-resistant mutants were induced in one Campylob

237 ampylobacter and four Enterococcus) obtained macrolide-resistant mutants, including two strains from

238 ermine the cause of skin ulcers and identify macrolide-resistant mutations before and 6 and 12 months

239 Macrolide-resistant Mycoplasma pneumoniae is an increasi

240 Patients with macrolide-resistant organisms were less likely to have b

241 Erythromycin increased the proportion of macrolide-resistant oropharyngeal streptococci (median c

242 The macrolide-resistant phenotype was found in 50.8% of fema

243 was associated with increased circulation of macrolide-resistant S. pneumoniae carriage among young c

244 ce suggesting that patients hospitalized for macrolide-resistant S. pneumoniae pneumonia were more se

245 y in patients with (invasive or noninvasive) macrolide-resistant S. pneumoniae pneumonia, and no effe

246 However, other macrolide-resistant serotypes (eg, 15A and 35B) not curr

247 is not likely to achieve cure rates >80% in macrolide-resistant strains, in a similar range as recen

248 of asthma phenotypes, and help to identify a macrolide-responsive subgroup.

249 escribes the electrophysiological effects of macrolides, reviews literature indicating that the large

250 termittent three-times-weekly therapy with a macrolide, rifampin, and ethambutol is a reasonable init

251 tions of at least two chiral centers off the macrolide ring have no effect on PB activity.

252 e PB side chain, as well as a feature of the macrolide ring shared with herboxidiene, are required fo

253 terial natural product, contains a 12-member macrolide ring with an extended epoxide-containing side

254 Syntheses of two 14-membered macrolides Sch-725674 and Gliomasolide C are described h

255 proportion of wild-type 23 S rRNA (presumed macrolide sensitive) infections cured after 1.5g and azi

256 Further exploration of macrolides showed that KCNJ5MUT was similarly selectivel

257 strategy periods, 739 during the beta-lactam-macrolide strategy periods, and 888 during the fluoroqui

258 rval [CI], -0.6 to 4.4) with the beta-lactam-macrolide strategy than with the beta-lactam strategy an

259 igand hydrophobic interactions mimicking the macrolide structure of the natural FKBP binders FK506 an

260 Macrolides, such as clarithromycin and azithromycin, pos

261 Our goals were to determine the incidence of macrolide susceptibility in U.S. isolates, the validity

262 ution in erm(41), previously associated with macrolide susceptibility, was identified in 62 isolates

263 ssus subsp. abscessus will predict inducible macrolide susceptibility.

264 nucleotide substitution was associated with macrolide susceptibility.

265 in clarithromycin is necessary to determine macrolide susceptibility.

266 sted to possess the genotype associated with macrolide susceptibility.

267 isolates renders these species intrinsically macrolide susceptible.

268 63 samples that were identified as having a macrolide-susceptible genotype by the duplex PCR assay,

269 The proportions of macrolide-susceptible versus -resistant genotypes harbor

270 The duration of effect is longer for macrolides than other classes.

271 Some studies suggest better outcomes with macrolide therapy for critically ill patients with commu

272 f 2,561 patients] mortality with beta-lactam/macrolide therapy vs 23% [386 of 1,680] with beta-lactam

273 sk estimates were pooled from eight studies, macrolide therapy was still associated with a significan

274 udies with mortality endpoints that compared macrolide therapy with other regimens in critically ill

275 omoted displacement of H. influenzae by more macrolide-tolerant pathogens including P. aeruginosa.

276 and that amino acid sequences implicated in macrolide toxin binding are found in the dynactin compon

277 factor shows that the F-actin depolymerizing macrolide toxin mycalolide B (MB) rapidly and selectivel

278 Mycolactone is a complex macrolide toxin produced by Mycobacterium ulcerans, the

279 Macrolide treatment failure in syphilis patients is asso

280 Long-term macrolide treatment has proven benefit in inflammatory a

281 Prevention is based on prophylactic macrolide treatment, immunization starting at 6 weeks of

282 The selective pressures of widespread macrolide use and PCV7 and PCV13 introductions on S. pne

283 Macrolide use has increased, and substantial variation w

284 ngs argue for a cautious approach to chronic macrolide use in patients without P. aeruginosa airway i

285 patients with community-acquired pneumonia, macrolide use was associated with a significant 18% rela

286 In our primary analysis of 9,850 patients, macrolide use was associated with statistically signific

287 ntibiotics (cephalosporins, penicillins, and macrolides) used between age 3 months and age 4 years we

288 o received other regimens (cephalosporin and macrolide vs neither drug class).

289 cting AT domains for the biosynthesis of the macrolide was also demonstrated.

290 iprofloxacin, and moxifloxacin compared with macrolides were 1.75 (1.12-2.73), 1.87 (1.20-2.93), and

291 In cases of infection, macrolides were the first choice.

292 Penicillins and macrolides were the most common antibiotic categories pr

293 Unlike other macrolides, which carry several side chains, a single de

294 Rapamycin is a naturally occurring macrolide whose target is at the core of nutrient and st

295 e of apoptolidin A consists of a 20-membered macrolide with mono- and disaccharide moieties.

296 ung, and Blood Institute guideline-adherent (macrolide with parenteral cephalosporin) vs non-guidelin

297 urther in silico docking simulations of four macrolides with p110alpha subunits have been carried out

298 with d-desosamine, a quick entry to chimeric macrolides with potential antibiotic activity.

299 Cross-reactivity studies from other macrolides with similar structure were tested.

300 fficacy and safety of solithromycin, a novel macrolide, with moxifloxacin for treatment of CABP.